NCT06699966

Stony Brook Medicine Anti-Inflammatory Trial

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Stony Brook University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is an experimental study designed to measure the effect of celecoxib or minocycline on depressive symptoms in unipolar and bipolar depression. Participants will be equally randomized to either celecoxib or minocycline. All participants will complete a battery of clinical and psychological assessments prior to treatment assignment, and again after treatment completion, to assess any changes or improvements in depression.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Celecoxib	The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.
DRUG	Minocycline	Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.

Timeline

• Start date: 2026-01-01
• Primary completion: 2030-06-01
• Completion: 2031-01-01
• First posted: 2024-11-21
• Last updated: 2025-07-24

Regulatory

• FDA-regulated drug study